Downregulation of RUNX3 has a poor prognosis and promotes tumor progress in kidney cancer.

CONCLUSION: Targeting RUNX3 pathway and its promoter methylation are potential therapeutic strategies to treat kidney cancer.
PMID: 32600926 [PubMed - as supplied by publisher]

Source: Urologic Oncology - June 25, 2020 Category: Urology & Nephrology Authors: Zheng J, Mei Y, Zhai G, Zhao N, Jia D, Fan Y Tags: Urol Oncol Source Type: research